March 16, 2015 — Medtronic plc unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th Annual Scientific Session of the American College of Cardiology (ACC). The preclinical data showed controlled and efficacious drug elution into the arterial wall without a polymer carrier, while reducing diameter stenosis and achieving complete stent coverage quickly without inflammation. Based on these results, Medtronic plans to initiate a clinical trial in the coming months.
The first global DFS study will be conducted at multiple sites in geographies including Australia and Brazil. The clinical study will enroll 100 patients and will evaluate late lumen loss as measured by quantitative coronary angiography. Gregg W. Stone, M.D., director, cardiovascular research and education, Center for Interventional Vascular Therapy, Columbia University Medical Center, New York-Presbyterian Hospital, will serve as the global chairperson of the Global Clinical Program executive committee. The study co-principal investigators are Prof. Stephen Worthley of Royal Adelaide Hospital, Adelaide, Australia and Alexandre Abizaid, M.D., of Instituto Dante Pazzanese de Cardiologia, São Paolo, Brazil.
“Second-generation DES technologies have shown better clinical outcomes compared to first generation DES in a broad spectrum of patient anatomies and subsets; however, controlled polymer-free drug elution has the potential to further optimize acute performance, improve near-term and long-term clinical outcomes and potentially allow for a shorter DAPT [dual antiplatelet therapy] duration,” said Stone.
The DFS is built on the platform of the Resolute Integrity DES with Continuous Sinusoid technology (a Medtronic method of stent manufacturing that molds one single strand of wire into a sinusoidal wave enabling a continuous range of motion), as well as the next-generation Resolute Onyx DES with CoreWire technology that allows it to have a denser core metal surrounded by a cobalt alloy outer layer. The new DFS features a novel tri-layer wire design, which allows the innermost core layer to be removed so that the hollow strut lumen functions as an internal drug reservoir. The drug is eluted from the core upon implantation through abluminal side holes on the surface of the stent, which allows for controlled, polymer-free drug elution over a desired period of time directly into the arterial wall to potentially avoid chronic inflammation and adverse vascular responses.
“While investigating some of the latest innovations – including both bioabsorbable polymers and polymer-free technologies – we identified several potential drawbacks,” said Jason Weidman, vice president and general manager of the Medtronic coronary business. “The internally-loaded DFS has been developed to control drug release in the absence of a polymer carrier and eliminate inflammation due to polymer degradation.”
The Drug-Filled Stent is available for investigational use only and it is not approved for use outside of clinical studies. The Resolute Onyx DES received CE Mark in November 2014 and is an investigational device in the United States.
For more information: www.medtronic.com
July 25, 2024 
